Diabetic retinopathy (DR)
The #1 cause of blindness for working-age adults
See it before it starts. And stop it in its tracks.
80% of people with diabetes
will develop diabetic retinopathy (DR)
at some point in their lives.
Now 2030 2040
103,300,000 people were diagnosed with DR
76,000,000 people were diagnosed with Glaucoma
195,600,000 Cases of Age Related Macular Degeneration

The longer DR goes undetected, the greater the chance it will damage eyesight forever

Know why

What if…

… Doctors could eliminate the discomfort of retinal screening and make annual screening effortless?

What if doctors could eliminate the discomfort of retinal screening and make annual screening effortless?

We change eye care
with artificial intelligence

MONA is not

a retinal camera or a software inside a retinal camera


an AI software as a medical device compatible with pictures from most fundus cameras.

How MONA works

Until recently, screening for diabetic retinopathy could only be done by an ophthalmologist.
Thanks to MONA’s AI-driven solution, screening can now be done by a nurse or technician. That reduces bottlenecks and frees up access for patients.

So, how does it work?

Step 1:

A diabetic patient comes in for their annual screening.
A technician or nurse takes a retinal picture of each eye using a semi-automated non mydriatic fundus camera.


Step 2:

MONA’s AI algorithm screens the images for early signs of Diabetic Retinopathy and Diabetic Maculopathy.

MONA can detect referable Diabetic Retinopathy with a sensitivity of 90% while maintaining a specificity of 95%. MONA can also detect Diabetic Maculopathy with a sensitivity of 91% and a specificity of 94%.


Step 3:

Within seconds, MONA can detect whether the patient needs to be referred to an eye specialist or simply wait for their next annual exam.


Step 4:

Finally, a full report is generated in MONA’s web application and shared with the ophthalmologist. The entire process takes no more than 3 minutes.


We’re using AI to make DR screening more accessible and affordable.


537 million have diabetes in 2022 and it will grow to 783 million by 2045. MONA improves access to necessary retinal screening for a growing patient population.



MONA replaces inconvenient and uncomfortable screening techniques prevalent today by scanning retinal images for subtle DR markers. Catching them early makes it easier for physicians to treat DR-driven conditions, and stop them from damaging eyesight forever.



In a matter of seconds, MONA can detect if a patient needs to be referred to an eye specialist. An effortless 3 minute screening for patients, and more time for physicians to focus on treatment.


The science behind MONA

Deep Learning

MONA is an artificial intelligence diagnostic healthcare solution. Its deep learning algorithms have been tested, trained, and validated against more than 273,000 retinal images.

Immediate result

Within seconds, MONA detects referrable DR with a sensitivity of 90% and a specificity of 95%.
For non-proliferative and proliferative DR, MONA’s detection sensitivity rises to 99%.

Not only DR

For hard exudates that are predictive of macular edema, MONA detects with a sensitivity of 91% and a specificity of 94%.

Better for doctors. Better for patients.

MONA’s automated, AI-based retinal screening technology dramatically improves DR screening for both doctors and patients:


MONA makes screening easy and comfortable for patients. Its quick 3min-process also helps alleviate concerns about COVID-19 exposure from in-person appointments.

Impact on patients

medical experts

MONA improves the take-up of regular screening appointments and contributes to better health outcomes. Less time spent on screening, more time for treatment.

Impact on experts

The team behind MONA

We work to ensure every diabetes patient gets screened every year.

Get to know us

Seeing is believing

Want to learn more? Contact us to see the power of MONA in action.
Just complete the form below and we’ll be in touch with more information.


    Medical Experts Patients

    Impact on

    Diabetic retinopathy is the number one cause of blindness amongst working age adults.
    People with diabetes need to have an annual examination in order to identify DR at an early stage. Patients diagnosed with DR need regular screening to track the progress of the disease.

    MONA lets you have a regular eye exam without waitlists or physical discomfort.
    In minutes your doctor will tell you if you need further evaluation or if you can wait for your next annual exam.

    Medical Experts Patients

    Impact on
    medical experts

    Ophthalmologists can use MONA to improve patient workflow. A technician can capture retinal images and in 3 minutes you will know if the patient needs further care. Less time spent on diagnosis frees up time for more complex treatments and procedures. Patients will be more satisfied and likely to share positive experiences across their personal networks.

    Diabetologists and endocrinologists can use MONA to add eye care to their patient evaluations. An automated 3-minute process means patients leave reassured — or with a referral to an ophthalmologist.


    The issue

    With an ageing global population, eye disease is on the rise and demand for eye health services is increasing. 

    A 2020 study published in The Lancet found that diabetic retinopathy was a leading cause of blindness in those aged 50 years and older.

    The good news is that DR can be prevented and treated.
    But there are barriers that need to be overcome:

    Only specialists can diagnose

    • Current screening methods require analysis by a specialist to make a diagnosis and confirm which stage of DR has been reached.

    Waiting lists are long

    • With only a limited number of specialists in any location, there can be a long wait for an appointment.

    Screening can be unpleasant

    • Current techniques for retinal screening are time-consuming and physically uncomfortable.